大剂量rHuEPO治疗肾性贫血的临床研究  

Clinical Research on High Dose of rHuEPO Ohpatients for Renal Anemia

作　　者：郭振涛[1] 肖青[1] 李香玲[1] 陈静[1] 

机构地区：[1]潍坊医学院附属医院肾内科,山东潍坊261031

出　　处：《现代生物医学进展》2009年第12期2307-2309,共3页Progress in Modern Biomedicine

摘　　要：目的：探讨应用大剂量重组人促红细胞生成素（rHuEPO）治疗肾性贫血的效果及机制。方法：对38例处于慢性肾脏病（CKD）3～5期的贫血患者给予佳林豪1．2万IU皮下注射，每周1次，连续12周，同时补充铁剂、叶酸和维生素B12；骨髓穿刺进行铁染色和显微图像分析，比较治疗前后血清铁蛋白（SF）、血清铁（SI）及铁粒幼细胞计数，对总红系所占百分数（E（与SI、SF、红细胞压积（He0行相关分析，治疗前后取血检测红细胞压积（HCT）、RBC、血红蛋白（Hb）。结果：治疗过程中大部分患者在EPO注射12周后HCT、RBC、Hb均比用药前有显著增高，骨髓红系增生较治疗前明显活跃，各类幼红细胞比率及E（总红系所占百分数）均显著升高，其中以晚幼红增生最为明显，SI、SF及铁粒幼细胞计数均明显降低，治疗前后骨髓AE％与血ARBC％、AHCT％呈高度正相关，AE％与ASF％、铁粒幼细胞计数变化率呈中度负相关，AE％与ASI％两者呈低度负相关。结论：大剂量重组人促红细胞生成素治疗肾性贫血效果显著。Objective： To study the effect of high dose of rHuEPO for renal anemian on bone marrow and iron metabolism. Methods： 38 patients with renal anemia received 120001U per weeks of Jialinhao hypodermic injection subcutaneous for 12weeks, meanwhile they took folio acids, vitamins B12 and chalybeates. Before and after the cure, take a sample of blood to test HCT,RBC,Hb Bone marrow puncture and Bone marrow micrograph anlysis was performed,serum ferritin and serum iron before and after the therapy and their corre- lation were analyzed. Results： After the therapy, RBC, Hb, HCTincreased significantly, After the therapy marrow iron stain, serum fer- ritin and serum iron decreased significantly, correlation AE% strongly correlated with ARBC%, AHCT% （P〈0.001）. AE% negatively cor- related with the variety ratio of sideroblast counts, ASI% and ASF% （P〈0.05）. But ASI% and ASF% had no correlation with ARBC% and AHCT%. Conclusions： High dose of recombinant human erythropoietin treatment of renal anemia results significantly.

关 键 词：人类重组促红细胞生成素 肾性贫血 骨髓象 铁代谢 

分 类 号：R692[医药卫生—泌尿科学]